1.Comparison of Quantitation of Cytomegalovirus DNA by Real-Time PCR in Whole Blood with the Cytomegalovirus Antigenemia Assay.
Seonhee KWON ; Bo Kyeung JUNG ; Sun Young KO ; Chang Kyu LEE ; Yunjung CHO
Annals of Laboratory Medicine 2015;35(1):99-104
BACKGROUND: Quantitation of cytomegalovirus (CMV) DNA using real-time PCR has been utilized for monitoring CMV infection. However, the CMV antigenemia assay is still the 'gold standard' assay. There are only a few studies in Korea that compared the efficacy of use of real-time PCR for quantitation of CMV DNA in whole blood with the antigenemia assay, and most of these studies have been limited to transplant recipients. METHOD: 479 whole blood samples from 79 patients, falling under different disease groups, were tested by real-time CMV DNA PCR using the Q-CMV real-time complete kit (Nanogen Advanced Diagnostic S.r.L., Italy) and CMV antigenemia assay (CINA Kit, ArgeneBiosoft, France), and the results were compared. Repeatedly tested patients were selected and their charts were reviewed for ganciclovir therapy. RESULTS: The concordance rate of the two assays was 86.4% (Cohen's kappa coefficient value=0.659). Quantitative correlation between the two assays was a moderate (r=0.5504, P<0.0001). Among 20 patients tested repeatedly with the two assays, 13 patients were transplant recipients and treated with ganciclovir. Before treatment, CMV was detected earlier by real-time CMV DNA PCR than the antigenemia assay, with a median difference of 8 days. After treatment, the antigenemia assay achieved negative results earlier than real-time CMV DNA PCR with a median difference of 10.5 days. CONCLUSIONS: Q-CMV real-time complete kit is a useful tool for early detection of CMV infection in whole blood samples in transplant recipients.
Antiviral Agents/therapeutic use
;
Cytomegalovirus/*genetics
;
Cytomegalovirus Infections/drug therapy/pathology/virology
;
DNA, Viral/*blood/metabolism
;
Ganciclovir/therapeutic use
;
Humans
;
*Immunoassay
;
Organ Transplantation
;
Phosphoproteins/genetics/immunology/*metabolism
;
*Real-Time Polymerase Chain Reaction
;
Viral Matrix Proteins/genetics/immunology/*metabolism
;
Virology/*methods
2.The effect of short hairpin RNA and DNAzyme gene therapy on latent membrane protein-1 expression in nasopharyngeal carcinoma.
Yiqin WANG ; Suling HONG ; Yucheng YANG ; Di QIAN ; Xia KE
Journal of Clinical Otorhinolaryngology Head and Neck Surgery 2010;24(6):270-272
OBJECTIVE:
To study the inhibitory effects of short hairpin RNA (pshLMP1) combined with DNAzyme or alone on latent membrane protein-1 (LMP1)expression in HNE1 cell lines.
METHOD:
The pshLMP1 and DNAzymes were co-transfected with pEGFP-N1-1158 (a expression vector encoding LMP1 and EGFP fusion protein) into HNE1 cells, divided into 4 groups as positive control, RNA interference, combining and DNAzyme groups. The green fluorescence were analyzed and then the mRNA and protein of LMP1 gene were detected.
RESULT:
The HNE1 cells expressing green fluorescence in combining group were significantly less than that in RNA interference group (P < 0.01); The inhibition efficiency of green fluorescence in combining group were 86. 31% Wp 88.88% ,which were higher than that in RNA interference group with 75.15%. The detection of LMP1 mRNA and proteins showed that combining group had a higher inhibition ability.
CONCLUSION
Combining gene therapy with pshLMP1 and DNAzyme is superior to pshLMP1 alone to inhibit LMP1 gene expression.
Cell Line, Tumor
;
DNA, Catalytic
;
therapeutic use
;
Exons
;
Gene Expression Regulation, Viral
;
Genetic Therapy
;
Humans
;
Nasopharyngeal Neoplasms
;
genetics
;
metabolism
;
pathology
;
RNA, Small Interfering
;
genetics
;
therapeutic use
;
Transfection
;
Viral Matrix Proteins
;
genetics
3.Pediatric B-cell Lymphoma, Unclassifiable, With Intermediate Features Between Those of Diffuse Large B-cell Lymphoma and Burkitt Lymphoma: A Report of Two Cases.
Shanxiang ZHANG ; David WILSON ; Magdalena CZADER
Annals of Laboratory Medicine 2015;35(2):254-256
No abstract available.
Adolescent
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
;
Burkitt Lymphoma/*pathology
;
Child, Preschool
;
Cyclophosphamide/therapeutic use
;
Doxorubicin/therapeutic use
;
Female
;
Gene Rearrangement
;
Herpesvirus 4, Human/metabolism
;
Humans
;
Immunohistochemistry
;
Lymphoma, B-Cell/*diagnosis/drug therapy
;
Lymphoma, Large B-Cell, Diffuse/*pathology
;
Male
;
Prednisone/therapeutic use
;
Proto-Oncogene Proteins c-myc/genetics
;
Tomography, X-Ray Computed
;
Vincristine/therapeutic use
;
Viral Matrix Proteins/immunology/metabolism
4.LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer.
Yi ZENG ; Yong Feng SI ; Gui Ping LAN ; Zhan WANG ; Ling ZHOU ; Min Zhong TANG ; O Brien SJ ; Jiao LAN ; Xiang Yang ZHOU ; Yong Li WANG ; Juan TANG ; Zhi Xiang ZHOU ; Hai Jun DU ; Hui LIN
Biomedical and Environmental Sciences 2020;33(11):849-856
Objective:
To evaluate the safety and effectiveness of a vaccine based on latent membrane protein 2 (LMP2) modified dendritic cells (DCs) that boosts specific responses of cytotoxic T lymphocytes (CTLs) to LMP2 before and after intradermal injection in patients with nasopharyngeal carcinoma (NPC).
Methods:
DCs were derived from peripheral blood monocytes of patients with NPC. We prepared LMP2-DCs infected by recombinant adenovirus vector expressing LMP2 (rAd-LMP2). NPC patients were immunized with 2 × 10
Results:
We demonstrated that DCs derived from monocytes displayed typical DC morphologies; the expression of LMP2 in the LMP2-DCs vaccine was confirmed by immunocytochemical assay. Twenty-nine patients with NPC were enrolled in this clinical trial. The LMP2-DCs vaccine was well tolerated in all of the patients. Boosted responses to LMP2 peptide sub-pools were observed in 18 of the 29 patients with NPC. The follow-up data of 29 immunized patients from April, 2010 to April 2015 indicated a five-year survival rate of 94.4% in responders and 45.5% in non-responders.
Conclusion
In this pilot study, we demonstrated that the LMP2-DCs vaccine is safe and effective in patients with NPC. Specific CTLs responses to LMP2 play a certain role in controlling and preventing the recurrence and metastasis of NPC, which warrants further clinical testing.
Adult
;
Aged
;
Cancer Vaccines/therapeutic use*
;
China
;
Dendritic Cells/immunology*
;
Female
;
Humans
;
Immunotherapy/methods*
;
Injections, Intradermal
;
Male
;
Middle Aged
;
Nasopharyngeal Carcinoma/therapy*
;
Nasopharyngeal Neoplasms/therapy*
;
T-Lymphocytes, Cytotoxic/immunology*
;
Viral Matrix Proteins/therapeutic use*
;
Young Adult
5.Expression and significance of p53-related proteins and LMP-1 in nasal NK/T-cell lymphoma.
Gang XU ; Huai-fu WANG ; Gang HE ; Ke XIE
Chinese Journal of Oncology 2009;31(5):351-355
OBJECTIVETo investigate the expression of murine double minute 2 (mdm2), p53, p21 and latent membrane protein 1 (LMP-1) in nasal NK/T-cell lymphoma (NKTL) and analyze their relationship with the clinical stage and prognosis.
METHODSThe clinicopathological and follow-up data of 62 patients with NKTL proven by pathology were collected. Paraffin-embedded tissue sections were examined for mdm2, p53, p21 and LMP-1 proteins by tissue microarray technique and immunohistochemistry. In situ hybridization was used to detect EBER1/2.
RESULTSThe positive expression rates of mdm2, p53, p21 and LMP-1 proteins in NKTL were 61.3%, 79.0%, 58.1% and 48.4%, respectively, and EBER1/2 was 90.3%. The positive expression rates of mdm2 in Ann Arbor stage I, II, III and IV NKTL were 43.5%, 62.5%, 73.3% and 87.5%, respectively; p53 were 69.6%, 75.0%, 86.7% and 100.0%; p21 were 47.8%, 56.3%, 60.0% and 87.5%; while those of LMP-1 were 60.9%, 50.0%, 26.7% and 50.0%, respectively. With the progression of tumor, the positive expression rates of mdm2, p53 and p21 proteins gradually increased. There were statistically significant differences between them (P<0.05). There were statistically positive correlations among those three genes (P<0.05). The prognosis of the positive expression group of these three genes was worse than that of negative expression group (P<0.05). No statistically significant difference was observed between the expression of LMP-1 protein and the clinical stage or prognosis (P>0.05). The expression of p53 protein was an independent prognostic factor.
CONCLUSIONThe expression of mdm2, p53 and p21 proteins is closely related with the pathogenesis and progression of NKTL. They are good markers for judgement of the biological behavior of NKTL. The expression of p53 protein is an independent prognostic factor. Though no significant relationship was found between the expression of LMP-1 protein and the clinical stage or prognosis, it may play some role in tumor progression.
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cyclin-Dependent Kinase Inhibitor p21 ; metabolism ; Cyclophosphamide ; therapeutic use ; Doxorubicin ; therapeutic use ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Extranodal NK-T-Cell ; drug therapy ; metabolism ; pathology ; radiotherapy ; Male ; Middle Aged ; Neoplasm Staging ; Nose Neoplasms ; drug therapy ; metabolism ; pathology ; radiotherapy ; Prednisone ; therapeutic use ; Proto-Oncogene Proteins c-mdm2 ; metabolism ; RNA, Viral ; metabolism ; Survival Rate ; Tumor Suppressor Protein p53 ; metabolism ; Vincristine ; therapeutic use ; Viral Matrix Proteins ; metabolism ; Young Adult
6.Research progress of anti-influenza virus agents.
Qiang ZHANG ; Qing-jie ZHAO ; Rui-sheng XIONG ; Jian-feng LI ; Jing-shan SHEN
Acta Pharmaceutica Sinica 2010;45(3):289-299
Influenza is a major threat to millions of people worldwide. Vaccines and antiviral agents are two main options available to reduce the impact of the influenza virus, while anti-influenza agents are the most effective means to prevent the transmission of the highly contagious virus and to treat the epidemics of disease. At present, four anti-influenza agents have been approved by the FDA for the treatment of influenza, including two M2 protein ion channel inhibitors-amantadine and rimantadine and two neuraminidase inhibitors-zanamivir and oseltamivir. Arbidol hydrochloride, launched in Russia, is a potent inhibitor of influenza virus, too. Neuraminidase inhibitors could be classified generally by structure into six different kinds: sialic acid derivatives, benzoic acid derivatives, cyclohexene derivatives, cyclopentane derivatives, pyrrolidine derivatives and natural products. In this paper, recent progress in the research of the action mechanisms and structure-activity relationships of these anti-influenza virus agents were reviewed.
Amantadine
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Antiviral Agents
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Cyclopentanes
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Guanidines
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Humans
;
Indoles
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Influenza, Human
;
drug therapy
;
Neuraminidase
;
antagonists & inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Orthomyxoviridae
;
drug effects
;
Oseltamivir
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Pyrrolidines
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Rimantadine
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Structure-Activity Relationship
;
Viral Matrix Proteins
;
antagonists & inhibitors
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
;
Zanamivir
;
chemical synthesis
;
chemistry
;
pharmacology
;
therapeutic use
7.Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: clinicopathologic characterization of 16 cases showing different patterns.
Lei WANG ; Weige WANG ; Xiaoqiu LI ; Ye GUO ; Xiongzeng ZHU
Chinese Journal of Pathology 2014;43(5):307-312
OBJECTIVETo profile the clinicopathologic features of a series of grey zone lymphoma (GZL) cases with hybrid features of diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (CHL), with a purpose to gain an in-depth understanding of the borderline B-cell neoplasm.
METHODSThe clinical, morphologic and immunophenotyical characteristics of 16 cases were retrospectively analyzed.
RESULTSThe patients were mostly male adults, with a male to female ratio of 1.7: 1.0 and a mean age of 40.2 years. Eight patients presented with peripheral nodal lesions and five cases with mediastinal involvement. Histologically and immunophenotypically, the 16 cases were classified into three sub-categories. In 4 cases, the morphologic features resembled CHL more closely, but the neoplastic cells showed uniform and intense positive staining of CD20 (pattern 1). Although the initial impression of the other 8 cases was that of DLBCL, the expression levels of CD20 and PAX5 were variable, and CD30 or CD15 was positive (pattern 2). A characteristic feature of pattern 3, observed in the remaining 4 cases, demonstrated a broad spectrum of morphology with hybrid features of both CHL and DLBCL. The neoplastic cells in pattern 3 were positive for CD20, CD30 and CD15. EBV-LMP1 was detected in 6 of the 11 tested cases. Clinically, most patients with GZL seemed insensitive to immuno-chemotherapy of the R-CHOP regimen.
CONCLUSIONSThe diagnostic criteria for GZL with features intermediate between DLBCL and CHL is proposed by the three histologic patterns commonly seen in these lesions. Cases presented with peripheral lesions might differ from those with mediastinal presentation pathologically. At current time, there is no effective treatment for these borderline B-cell lymphomas and the prognosis is poor.
Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Murine-Derived ; therapeutic use ; Antigens, CD20 ; metabolism ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cyclophosphamide ; therapeutic use ; Diagnosis, Differential ; Doxorubicin ; therapeutic use ; Female ; Hodgkin Disease ; drug therapy ; metabolism ; pathology ; Humans ; Ki-1 Antigen ; metabolism ; Lewis X Antigen ; metabolism ; Lymphoma, Large B-Cell, Diffuse ; drug therapy ; metabolism ; pathology ; Male ; Middle Aged ; PAX5 Transcription Factor ; metabolism ; Prednisone ; therapeutic use ; Prognosis ; Retrospective Studies ; Rituximab ; Vincristine ; therapeutic use ; Viral Matrix Proteins ; metabolism ; Young Adult
8.Development of anti-influenza drug.
Tao ZHANG ; Cheng-Yu WANG ; Yu-Wei GAO ; Song-Tao YANG ; Tie-Cheng WANG ; Xian-Zhu XIA
Chinese Journal of Virology 2011;27(5):475-480
Animals
;
Antiviral Agents
;
pharmacology
;
therapeutic use
;
DNA-Directed RNA Polymerases
;
antagonists & inhibitors
;
Drug Discovery
;
Hemagglutinin Glycoproteins, Influenza Virus
;
chemistry
;
metabolism
;
Humans
;
Influenza A virus
;
drug effects
;
genetics
;
metabolism
;
Influenza, Human
;
drug therapy
;
Molecular Targeted Therapy
;
Neuraminidase
;
antagonists & inhibitors
;
RNA-Binding Proteins
;
antagonists & inhibitors
;
Signal Transduction
;
drug effects
;
Viral Core Proteins
;
antagonists & inhibitors
;
Viral Matrix Proteins
;
antagonists & inhibitors
9.Surveillance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic hematopoietic stem cell transplantation.
Jin-Song JIA ; Dong-Ping LIU ; Xiao-Jun HUANG ; Tong WU ; Dai-Hong LIU ; Yao-Chen ZHANG ; Hong SU ; Jing-Bo WANG ; Jia-Rui ZHOU ; Qiang LIU ; Min-Yu YING ; Rui-Juan SUN ; Xuan DUAN ; Dao-Pei LU
Journal of Experimental Hematology 2006;14(4):749-754
The study was aimed to investigate the pp65 antigen of human cytomegalovirus (CMV) and its clinical significance in patients revived allogeneic hematopoietic stem cell transplantation (HSCT). 104 patients received allogeneic HSCT were studied. Anticoagulant blood samples were obtained from the recipients before and after transplantation and in the convalescence. CMV pp65 antigen in leukocytes was detected by indirect immunofluorescence assay using CMV Brite Kit weekly. The results showed that among the 104 patients, 29 cases were CMV pp65 positive (27.88%). Out of 29 cases 16 were CMV antigenemia and 13 cases were CMV disease. There were 25 cases who positively responded to antiviral therapy (effective ratio 86.21%) and 4 cases died (case-fatality ratio 13.79%). The detection revealed a significant difference in the incidence of CMV infection between the patients received unrelated or haploidentical family donor HSCT (39.29%) and HLA-identical sibling donor HSCT (14.58%) (P < 0.05). The incidence rate of CMV infection in patients with 0-I grade aGVHD and patients with II-IV grade aGVHD were 19.44% and 46.88% respectively, which had significant difference (P < 0.05). There was significant difference in the occurrence of aGVHD between the patients with and without positive CMV pp65 (P < 0.05). It is concluded that infection of CMV can be detected by the CMV pp65 monoclonal fluorescence immunohistochemistry, The detection of CMV pp65 antigen in peripheral blood leukocytes as a indicator for CMV disease surveillance after HSCT, which may be used to early diagnose the CMV infection, to guide the antiviral treatment and evaluate its efficacy.
Adolescent
;
Adult
;
Antiviral Agents
;
therapeutic use
;
Child, Preschool
;
China
;
epidemiology
;
Cytomegalovirus
;
immunology
;
Cytomegalovirus Infections
;
diagnosis
;
drug therapy
;
epidemiology
;
Female
;
Graft vs Host Disease
;
epidemiology
;
Hematopoietic Stem Cell Transplantation
;
adverse effects
;
Humans
;
Leukocytes
;
virology
;
Male
;
Middle Aged
;
Phosphoproteins
;
blood
;
Risk Factors
;
Viral Matrix Proteins
;
blood